Ascletis Pharma Inc. has distributed the proxy form and agenda for its 2026 Annual General Meeting (AGM), scheduled for 09:00 a.m. on Monday, 29 June 2026 at Four Seasons Hotel Hong Kong, 8 Finance Street, Central, Hong Kong.

Key proposals to be put to shareholders are summarised below:

1. 2025 Financial Statements • Shareholders will vote on receiving and considering the audited consolidated financial statements for the year ended 31 December 2025, together with the directors’ and auditor’s reports.

2. Board Composition and Remuneration • Dr. Jinzi Jason Wu is nominated for re-election as Executive Director. • Mr. Jiong Gu is nominated for re-election as Independent Non-Executive Director. • The board seeks authority to determine directors’ remuneration.

3. Auditor Re-appointment • KPMG is proposed for re-appointment as the Company’s auditor, with the board authorised to fix its remuneration.

4. Share Issuance Mandate • Directors request a general mandate to allot, issue, and deal with shares— including any sale or transfer of treasury shares—up to 20 % of the Company’s issued share capital (excluding any treasury shares).

5. Share Repurchase Mandate • A complementary mandate authorises the repurchase of shares up to 10 % of issued share capital (excluding any treasury shares), with repurchased shares permitted to be held in treasury.

6. Extension Mandate • The share issuance mandate may be extended by the aggregate number of shares repurchased under the above authority.

7. Amended Memorandum & Articles • A special resolution proposes adoption of the third amended and restated memorandum and articles of association, incorporating revisions detailed in Appendix III of the AGM circular. A director will be authorised to complete all related formalities.

Proxy Arrangements • Registered shareholders wishing to vote by proxy must lodge the completed form with Computershare Hong Kong Investor Services Limited, 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong, no later than 09:00 a.m. on Saturday, 27 June 2026.

The AGM will proceed as scheduled unless adjourned, and completion of a proxy form does not preclude shareholders from attending and voting in person.